Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents
This study has been completed.
Sponsor:
Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
Information provided by (Responsible Party):
Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
ClinicalTrials.gov Identifier:
NCT01407978
First received: March 30, 2010
Last updated: May 18, 2012
Last verified: May 2012
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Received Date ICMJE | March 30, 2010 | ||||||||
Last Updated Date | May 18, 2012 | ||||||||
Start Date ICMJE | August 2009 | ||||||||
Primary Completion Date | March 2010 (final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures ICMJE |
Incidence of adverse events [ Time Frame: 21-28 days after vaccination ] [ Designated as safety issue: Yes ] | ||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||
Change History | Complete list of historical versions of study NCT01407978 on ClinicalTrials.gov Archive Site | ||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||
Current Other Outcome Measures ICMJE | |||||||||
Original Other Outcome Measures ICMJE | |||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents | ||||||||
Official Title ICMJE | Tolerability and Immunogenicity Study of FLUVAL P H1N1 Monovalent Influenza Vaccine of Omninvest in Children and Adolescents | ||||||||
Brief Summary | This is a single-blind, reference drug controlled study to assess safety and tolerability of FLUVAL P H1N1 monovalent influenza vaccine (whole virus, inactivated, adjuvanted with alumn phosphate gel) containing 6 mcgHA per 0.5mL active ingredient in children and adolescents. To assess, as secondary objective, the efficacy (immunogenicity) of the vaccine by serology testing. |
||||||||
Detailed Description | Primary Objective:
Secondary Objectives:
|
||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase | |||||||||
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Prevention |
||||||||
Condition ICMJE |
|
||||||||
Intervention ICMJE |
|
||||||||
Study Arm (s) |
|
||||||||
Publications * | |||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Completed | ||||||||
Enrollment ICMJE | 58 | ||||||||
Completion Date | March 2010 | ||||||||
Primary Completion Date | March 2010 (final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Gender | Both | ||||||||
Ages | 3 Years to 18 Years | ||||||||
Accepts Healthy Volunteers | Yes | ||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||
Location Countries ICMJE | Hungary | ||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT01407978 | ||||||||
Other Study ID Numbers ICMJE | FLUVAL P-H-07 | ||||||||
Has Data Monitoring Committee | Yes | ||||||||
Responsible Party | Omninvest Vaccine Manufacturing, Researching and Trading Ltd. | ||||||||
Study Sponsor ICMJE | Omninvest Vaccine Manufacturing, Researching and Trading Ltd. | ||||||||
Collaborators ICMJE | |||||||||
Investigators ICMJE |
|
||||||||
Information Provided By | Omninvest Vaccine Manufacturing, Researching and Trading Ltd. | ||||||||
Verification Date | May 2012 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |